Adjunctive xanomeline/trospium in clozapine-resistant schizophrenia: two case reports demonstrating limited response
Therapeutic Advances in Psychopharmacology
Published online on March 27, 2026
Abstract
Therapeutic Advances in Psychopharmacology, Volume 16, XX 2026.
Few pharmacologic options exist for patients with clozapine-resistant schizophrenia (CRS) or schizoaffective disorder. Xanomeline/trospium represents a new class of antipsychotic medication that has efficacy as monotherapy for schizophrenia. Despite ...
Few pharmacologic options exist for patients with clozapine-resistant schizophrenia (CRS) or schizoaffective disorder. Xanomeline/trospium represents a new class of antipsychotic medication that has efficacy as monotherapy for schizophrenia. Despite ...